GILEAD SCIENCES, INC.

GILD 10-Q · Q3 2025
API behind this page

GILD Q3 2025 request

Playground key active
Request URL /api/financials?ticker=GILD&year=2025&quarter=3
waiting 0 ms 
Pick an endpoint and run the request.
curl

Income Statement

JSON CSV Excel
Income Statement
Metric Q3 2025 Q3 2024 YoY
Revenue 7,769 7,545 +3.0%
Show Product Lines breakouts
AmBisome 123 130 -5.4%
AmBisome · Europe 69 71 -2.8%
AmBisome · Rest of World 52 52 0.0%
AmBisome · US 2 6 -66.7%
Biktarvy 3,686 3,472 +6.2%
Biktarvy · Europe 427 375 +13.9%
Biktarvy · Rest of World 320 272 +17.6%
Biktarvy · US 2,940 2,826 +4.0%
Descovy 701 586 +19.6%
Descovy · Europe 23 24 -4.2%
Descovy · Rest of World 25 28 -10.7%
Descovy · US 652 534 +22.1%
Genvoya 377 449 -16.0%
Genvoya · Europe 34 44 -22.7%
Genvoya · Rest of World 19 21 -9.5%
Genvoya · US 323 384 -15.9%
Odefsey 277 326 -15.0%
Odefsey · Europe 61 69 -11.6%
Odefsey · Rest of World 10 9 +11.1%
Odefsey · US 206 248 -16.9%
Other 61 71 -14.1%
Other HIV 112 100 +12.0%
Other HIV · Europe 22 26 -15.4%
Other HIV · Rest of World 9 9 0.0%
Other HIV · US 82 65 +26.2%
Other Liver Disease 231 116 +99.1%
Other Liver Disease · Europe 81 54 +50.0%
Other Liver Disease · Rest of World 17 17 0.0%
Other Liver Disease · US 132 45 +193.3%
Other · Europe 7 8 -12.5%
Other · Rest of World 20 16 +25.0%
Other · US 34 47 -27.7%
Product 7,345 7,515 -2.3%
Product · Europe 1,144 1,154 -0.9%
Product · Rest of World 928 928 0.0%
Product · US 5,274 5,433 -2.9%
Royalty, contract and other revenues 424 30 +1313.3%
Royalty, contract and other revenues · Europe 411 13 +3061.5%
Royalty, contract and other revenues · Rest of World 5 1 +400.0%
Royalty, contract and other revenues · US 7 17 -58.8%
Sofosbuvir/Velpatasvir 309 385 -19.7%
Sofosbuvir/Velpatasvir · Europe 65 67 -3.0%
Sofosbuvir/Velpatasvir · Rest of World 97 96 +1.0%
Sofosbuvir/Velpatasvir · US 146 222 -34.2%
Symtuza - Revenue share 124 139 -10.8%
Symtuza - Revenue share · Europe 26 33 -21.2%
Symtuza - Revenue share · Rest of World 3 3 0.0%
Symtuza - Revenue share · US 95 103 -7.8%
Tecartus 83 98 -15.3%
Tecartus · Europe 35 29 +20.7%
Tecartus · Rest of World 8 6 +33.3%
Tecartus · US 40 63 -36.5%
Total Cell Therapy 432 485 -10.9%
Total Cell Therapy · Europe 186 211 -11.8%
Total Cell Therapy · Rest of World 83 66 +25.8%
Total Cell Therapy · US 163 208 -21.6%
Total HIV 5,277 5,073 +4.0%
Total HIV · Europe 592 570 +3.9%
Total HIV · Rest of World 386 342 +12.9%
Total HIV · US 4,299 4,161 +3.3%
Total Liver Disease 819 733 +11.7%
Total Liver Disease · Europe 158 132 +19.7%
Total Liver Disease · Rest of World 247 207 +19.3%
Total Liver Disease · US 414 393 +5.3%
Total Oncology 788 816 -3.4%
Total Oncology · Europe 275 291 -5.5%
Total Oncology · Rest of World 129 92 +40.2%
Total Oncology · US 384 433 -11.3%
Total Other 184 201 -8.5%
Total Other · Europe 76 80 -5.0%
Total Other · Rest of World 72 68 +5.9%
Total Other · US 36 53 -32.1%
Trodelvy 357 332 +7.5%
Trodelvy · Europe 89 80 +11.2%
Trodelvy · Rest of World 47 26 +80.8%
Trodelvy · US 221 226 -2.2%
Veklury 277 692 -60.0%
Veklury · Europe 43 81 -46.9%
Veklury · Rest of World 93 219 -57.5%
Veklury · US 140 393 -64.4%
Vemlidy 280 232 +20.7%
Vemlidy · Europe 12 11 +9.1%
Vemlidy · Rest of World 132 95 +38.9%
Vemlidy · US 136 126 +7.9%
Yescarta 349 387 -9.8%
Yescarta · Europe 151 182 -17.0%
Yescarta · Rest of World 75 60 +25.0%
Yescarta · US 123 145 -15.2%
Show Geography breakouts
Europe 1,555 1,167 +33.2%
Rest of World 933 929 +0.4%
US 5,281 5,450 -3.1%
Show Equity Components breakouts
Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income -15 14 -207.1%
Cost of Revenue 1,569 1,574 -0.3%
Research And Development Expense Excluding Acquired In Process Cost 1,346 1,395 -3.5%
Research And Development Asset Acquired Other Than Through Business Combination Written Off 170 505 -66.3%
Selling, General & Administrative 1,357 1,433 -5.3%
Show Business Segments breakouts
Reportable Segment 1,357 1,433 -5.3%
Total Costs & Expenses 4,442 6,657 -33.3%
Operating Income 3,327 888 +274.7%
Interest Expense 256 238 +7.6%
Non-Operating Income (Expense) -569 -306 -85.9%
Income Before Taxes 3,641 956 +280.9%
Income Tax Expense (Benefit) 589 -297 +298.3%
Show Equity Components breakouts
Income tax (benefit) expense · Reclassification Out Of Accumulated Other Comprehensive Income -2 2 -200.0%
Net Income 3,052 1,253 +143.6%
Show Equity Components breakouts
Retained Earnings 3,052 1,253 +143.6%
Net Income 3,052 1,253 +143.6%
EPS (Basic) 2.46 1 +146.0%
EPS (Diluted) 2.43 1 +143.0%
Wtd Avg Shares (Basic) 1,243 1,247 -0.3%
Wtd Avg Shares (Diluted) 1,254 1,254 0.0%
Sales & Marketing (Q) — — —
Show Business Segments breakouts
Reportable Segment 829 848 -2.2%
General & Administrative (Q) — — —
Show Business Segments breakouts
Reportable Segment 527 584 -9.8%
Other Non-Operating Income (Expense) 1 4 -75.0%
Comprehensive Income 3,107 1,233 +152.0%
Other Comprehensive Income Loss Cash Flow Hedge Gain Loss Before Reclassification After Tax 51 -74 +168.9%

Balance Sheet

Balance Sheet
Metric Q3 2025 Q3 2024 YoY
Current Assets
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 7,330 5,037 +45.5%
Marketable Securities (Current) 19 — —
Accounts Receivable 5,095 4,587 +11.1%
Inventory 1,785 1,869 -4.5%
Prepaid Expenses & Other Current Assets 3,645 3,287 +10.9%
Total Current Assets 17,874 14,779 +20.9%
Non-Current Assets
Property, Plant & Equipment 5,500 — —
Marketable Securities (Non-Current) 2,005 — —
Goodwill 8,314 8,314 0.0%
Deferred Tax Assets 1,998 — —
Other Non-Current Assets 4,873 5,494 -11.3%
Total Assets 58,533 54,525 +7.4%
Intangible Assets 15,270 17,656 -13.5%
Show Finite Lived Intangible Assets By Major Class breakouts
Hepcludex [Member] 451 537 -16.0%
Intangible asset – axicabtagene ciloleucel 4,084 4,491 -9.1%
Intangible asset – sofosbuvir 2,447 3,146 -22.2%
Other Intangible Assets 451 565 -20.2%
Trodelvy 7,836 8,917 -12.1%
Other Assets
Intangible Assets Net Excluding Goodwill 17,970 20,546 -12.5%
Current Liabilities
Accounts Payable 808 903 -10.5%
Accrued Rebates 4,931 4,113 +19.9%
Debt Current 2,806 1,812 +54.9%
Other Liabilities Current 3,752 — —
Total Current Liabilities 12,298 11,725 +4.9%
Current Portion of Long-Term Debt 2,806 1,812 +54.9%
Non-Current Liabilities
Long-Term Debt 22,135 21,437 +3.3%
Accrued Income Taxes Noncurrent 866 782 +10.7%
Deferred Tax Liabilities 597 794 -24.8%
Other Non-Current Liabilities 1,182 1,396 -15.3%
Long-Term Debt 24,941 23,249 +7.3%
Show Debt Instrument breakouts
1.20% Senior Unsecured Notes Due October 2027 · Senior Notes 749 748 +0.1%
1.65% Senior Unsecured Notes Due October 2030 · Senior Notes 996 995 +0.1%
2.60% Senior Unsecured Notes Due October 2040 · Senior Notes 989 989 0.0%
2.80% Senior Unsecured Notes Due October 2050 · Senior Notes 1,479 1,479 0.0%
2.95% Senior Unsecured Notes Due March 2027 · Senior Notes 1,249 — —
3.65% Senior Unsecured Notes Due March 2026 · Senior Notes 2,749 — —
4.00% Senior Unsecured Notes Due September 2036 · Senior Notes 744 — —
4.15% Senior Unsecured Notes Due March 2047 · Senior Notes 1,730 — —
4.50% Senior Unsecured Notes Due February 2045 · Senior Notes 1,736 — —
4.60% Senior Unsecured Notes Due September 2035 · Senior Notes 994 — —
4.75% Senior Unsecured Notes Due March 2046 · Senior Notes 2,225 — —
4.80% Senior Unsecured Notes Due April 2044 · Senior Notes 1,738 — —
4.80% Senior Unsecured Notes Due In November 2029 · Senior Notes 747 — —
5.10% Senior Unsecured Notes Due June 2035 · Senior Notes 991 — —
5.25% Senior Unsecured Notes Due October 2033 · Senior Notes 994 993 +0.1%
5.50% Senior Unsecured Notes Due November 2054 · Senior Notes 989 — —
5.55% Senior Unsecured Notes Due October 2053 · Senior Notes 989 988 +0.1%
5.60% Senior Unsecured Notes Due November 2064 · Senior Notes 739 — —
5.65% Senior Unsecured Notes Due December 2041 · Senior Notes 997 — —
Show Long-Term Debt Type breakouts
Notes Payable Other Payables 1,119 1,155 -3.1%
Stockholders' Equity
Common Stock 1 1 0.0%
Additional Paid-In Capital 8,678 7,327 +18.4%
Accumulated Other Comprehensive Income 36 73 -50.7%
Retained Earnings 12,825 11,073 +15.8%
Total Stockholders' Equity 21,540 18,475 +16.6%
Minority Interest -84 -84 0.0%
Stockholders Equity Including Portion Attributable To Noncontrolling Interest 21,456 18,390 +16.7%
Show Equity Components breakouts
Accumulated Gain Loss Net Cash Flow Hedge Parent -76 -27 -181.5%
Accumulated Net Unrealized Investment Gain Loss 7 — —
Accumulated Other Comprehensive Income 36 73 -50.7%
Accumulated Translation Adjustment 106 100 +6.0%
Additional Paid In Capital 8,678 7,327 +18.4%
Common Stock 1 1 0.0%
Noncontrolling Interest -84 -84 0.0%
Retained Earnings 12,825 11,073 +15.8%
Total Liabilities & Equity 58,533 54,525 +7.4%

Cash Flow Statement

Cash Flow Statement
Metric YTD Q3 2025 YTD Q3 2024 YoY
Operating Activities
Depreciation 280 286 -2.1%
Adjustment For Amortization 1,793 1,788 +0.3%
Stock-Based Compensation 664 613 +8.3%
Deferred Income Taxes 282 -1,465 +119.2%
Increase Decrease In Equity Securities Fv Ni -198 148 -233.8%
Other Non-Cash Items 213 294 -27.6%
Change in Accounts Receivable -546 67 -914.9%
Change in Inventory -913 -200 -356.5%
Change in Prepaid & Other Assets -275 -113 -143.4%
Change in Accounts Payable -37 348 -110.6%
Increase Decrease In Income Taxes -1,974 -1,268 -55.7%
Increase Decrease In Accrued Liabilities 401 -197 +303.6%
Net Cash from Operations 6,692 7,853 -14.8%
Investing Activities
Purchases of Investments -2,557 -244 -948.0%
Proceeds From Sale Of Available For Sale Securities Debt 514 2,265 -77.3%
Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities 32 327 -90.2%
Payments To Acquire Businesses Net Of Cash Acquired -461 -4,765 +90.3%
Payments To Acquire Other Investments -119 -453 +73.7%
Capital Expenditures -358 -376 +4.8%
Other Investing Activities -9 23 -139.1%
Net Cash from Investing -2,958 -3,224 +8.3%
Financing Activities
Proceeds From Issuance Of Common Stock 376 249 +51.0%
Share Repurchases -1,692 -800 -111.5%
Debt Repayments -1,780 -1,963 +9.3%
Payments Of Dividends -3,009 -2,945 -2.2%
Proceeds From Payments For Other Financing Activities -377 -234 -61.1%
Net Cash from Financing -6,482 -5,693 -13.9%
Other Cash Flow
Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents 87 15 +480.0%
Net Change in Cash -2,661 -1,049 -153.7%

Values in millions USD. Source: SEC EDGAR 10-Q filing.

This table is rendered from the same JSON returned by /api/financials.

Get API Key